Dr. Scagliotti Discusses the Future of Lung Cancer Therapy

Giorgio V. Scagliotti, MD, PhD
Published: Thursday, Sep 08, 2011



Giorgio V. Scagliotti, MD, PhD, head of the Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, believes that making a molecular diagnosis in solid tumors will become readily available in the future, not only in academic centers but also in the community setting. Molecular information will become critical in order to tailor systemic therapies to solid tumors, similar to how it is already being used in the field of hematologic malignancies.


Giorgio V. Scagliotti, MD, PhD, head of the Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, believes that making a molecular diagnosis in solid tumors will become readily available in the future, not only in academic centers but also in the community setting. Molecular information will become critical in order to tailor systemic therapies to solid tumors, similar to how it is already being used in the field of hematologic malignancies.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x